For health care professionals
You are about to leave AROMASIN.com. The information on the next site is intended
for health care professionals.
I am a health care professional. Take me to www.pfizeroncology.com.
I am not a health care professional. Take me back to www.aromasin.com.
AROMASIN® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).
Copyright © 2009 Pfizer Inc. All rights reserved.
The product information provided in this site is intended only for residents of
the United States. The products discussed herein may have different product labeling
in different countries.
The health information herein is provided for educational purposes only and is not
intended to replace discussions with a health care provider. All decisions regarding
patient care must be made with a health care provider, considering the unique characteristics
of the patient.
AOU00471
